Morgan Stanley Smith Barney have maintained their Buy recommendation but moved their Risk rating from High Risk to Medium, adjusted their estimates, and upgraded their target price to $0.64cpu from $0.43cpu to reflect the capital raising and reduced covenant risks. All bodes well for taking up the entitlement offer.
Add to My Watchlist
What is My Watchlist?